双能CT碘图影像组学分析用于鉴别胃癌T1/2与T3/4a分期:一项多中心研究
本研究纳入263例经手术病理确诊胃腺癌患者,利用双能CT静脉期碘图提取影像组学特征,结合肿瘤临床T分期、厚度、静脉期碘浓度、标准化动脉期碘浓度及Radscore构建列线图,在训练、验证及两个外部测试队列中鉴别T1/2与T3/4a期的AUC分别为0.892、0.846、0.894和0.821。
要点
- 列线图整合临床T分期、肿瘤厚度、静脉期碘浓度、标准化动脉期碘浓度及Radscore。
- 训练队列AUC 0.892(95%CI 0.829-0.956),验证队列AUC 0.846(95%CI 0.734-0.958)。
- 外部测试1队列AUC 0.894(95%CI 0.818-0.970),外部测试2队列AUC 0.821(95%CI 0.689-0.952)。
核心结论
- 基于双能CT碘图的影像组学模型联合双能CT定量参数及传统临床特征构建的多维个性化列线图,在术前识别胃癌T3/4a期方面表现出良好性能。
研究设计与样本
- 多中心研究,共纳入263例接受 upfront 手术且病理确诊胃腺癌患者,术前两周内行宝石光谱成像模式双期增强CT;回顾性收集151例(训练集105例、验证集46例),前瞻性收集112例(外部测试1集68例、外部测试2集44例)。
关键影像表现/征象
- 从静脉期碘图通过三维感兴趣区分割提取影像组学特征。
- 采用最小绝对收缩和选择算子进行特征选择。
- 使用随机森林、逻辑回归、朴素贝叶斯和支持向量机四种机器学习算法构建影像组学模型。
诊断标准与关键数值
- 列线图整合肿瘤临床T分期、肿瘤厚度、静脉期碘浓度、标准化动脉期碘浓度及Radscore(源自逻辑回归模型)。
- 训练队列鉴别T1/2与T3/4a期的AUC为0.892(95%CI 0.829-0.956)。
- 验证队列AUC为0.846(95%CI 0.734-0.958)。
- 外部测试1队列AUC为0.894(95%CI 0.818-0.970)。
- 外部测试2队列AUC为0.821(95%CI 0.689-0.952)。
临床应用与阅片要点
- 决策曲线证实列线图在广泛阈值概率范围内较默认简单策略提供更多净临床获益。
- 列线图可用于术前识别胃癌T3/4a期肿瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the value of radiomic analysis of dual-energy CT (DECT)-derived iodine maps (IMs) for the differentiation between T1/2 and T3/4a stage tumors in gastric cancer (GC).
METHODS: A total of 263 patients who received upfront surgery and were pathologically confirmed with gastric adenocarcinoma were enrolled in this study. Dual-phase enhanced CT scans with gemstone spectral imaging (GSI) mode were performed within two weeks before surgery. 151 patients were retrospectively collected for the training (n = 105) and validation (n = 46) cohorts, and 112 patients were prospectively collected for the external test1 (n = 68) and external test2 (n = 44) cohorts. According to the postoperative pathological T stage, patients were classified into T1/2 and T3/4a stage groups. Clinical characteristics were recorded and quantitative iodine concentration (IC) of tumors was measured. Radiomics features were extracted from the venous phase (VP) IMs by three-dimensional region of interest (3D-ROI) segmentation. Feature selection was performed using the least absolute shrinkage and selection operator. Four machine learning algorithms, including random forest, logistic regression, naive Bayes, and support vector machine, were used to construct radiomics models. Finally, the most valuable clinical characteristics, DECT parameters, and the best radiomics model were combined to build a nomogram. The diagnostic performance of nomogram was evaluated by the area under receiver operating characteristic curve (AUC), calibration curve, and decision curve.
RESULTS: The nomogram combined tumor clinical T stage (cT), tumor thickness, venous-phase iodine concentration (ICVP), normalized arterial-phase iodine concentration (nICAP), and Radscore (derived from logistic regression model). This integrated model demonstrated favorable performance in the differentiation between T1/2 and T3/4a stage tumors in GC, with AUCs of 0.892 (95 %CI: 0.829-0.956), 0.846 (95 %CI: 0.734-0.958), 0.894 (95 %CI: 0.818-0.970) and 0.821 (95 %CI: 0.689-0.952) observed for the training, validation, external test 1, and external test 2 cohorts, respectively. Hosmer-Lemeshow test showed a good fit (all P > 0.05). Decision curves confirmed that the nomogram provided more net clinical benefit than the default simple strategy over a wide range of threshold probabilities.
CONCLUSION: We have developed and validated a multidimensional personalized nomogram that integrates a radiomics model based on DECT-derived IMs, DECT quantitative parameters, and traditional clinical features. The proposed model demonstrated favorable performance in preoperative identification of T3/4a stage tumors in GC.
引用
- You Y, Liang Y, Chen L, et al. Radiomics analysis of dual-energy CT-derived iodine maps for differentiating between T1/2 and T3/4a in gastric cancer: A multicenter study. Eur J Radiol. 2025. PMID: 40121898. doi:10.1016/j.ejrad.2025.112054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。